Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug384 | BNT162b1 Wiki | 0.58 |
drug840 | Comparable Placebo of drug Wiki | 0.50 |
drug385 | BNT162b2 Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
drug454 | Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group Wiki | 0.50 |
drug383 | BNT162a1 Wiki | 0.50 |
drug2108 | NA-831 Wiki | 0.50 |
drug386 | BNT162b3 Wiki | 0.50 |
drug452 | Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group Wiki | 0.50 |
drug453 | Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group Wiki | 0.50 |
drug387 | BNT162c2 Wiki | 0.50 |
drug829 | Combination of oral polio vaccine and NA-831 Wiki | 0.50 |
drug458 | Biological: oral polio vaccine Wiki | 0.50 |
drug2574 | Placebo; 0.9% saline Wiki | 0.50 |
drug109 | AS03-adjuvanted SCB-2019 vaccine Wiki | 0.50 |
drug839 | Comparable Placebo of Oral Polio Vaccine and Placebo of drug Wiki | 0.50 |
drug838 | Comparable Placebo Wiki | 0.50 |
drug623 | COVID-19 convalescent plasma Wiki | 0.50 |
drug2490 | Placebo Wiki | 0.13 |
Name (Synonyms) | Correlation | |
---|---|---|
D012327 | RNA Virus Infections NIH | 0.50 |
D012141 | Respiratory Tract Infections NIH | 0.25 |
D018352 | Coronavirus Infections NIH | 0.24 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011947 | Respiratory tract infection HPO | 0.25 |
Navigate: Correlations HPO
There are 4 clinical trials
This trial has two parts. Part A, a dose finding part, with three dose escalation cohorts, one dose de-escalation cohort, three dose refinement cohorts, and up to three optional cohorts in older subjects. Part B, a part with expansion cohorts with dose levels which are selected using data generated in Part A. The vaccine BNT162b3 will be administered using a Prime/Boost (P/B) regimen.
Description: At 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, 162±7 days, and 365±14 days after the boost immunization.
Measure: Functional antibody responses. Time: up to 365 days following dose administrationDescription: At 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, 162±7 days, and 365±14 days after the boost immunization.
Measure: Fold increase in functional antibody titers. Time: up to 365 days following dose administrationDescription: At 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, 162±7 days, and 365±14 days after the boost immunization.
Measure: Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline. Time: up to 365 days following dose administrationThis is a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population. After randomization, the trial for each subject will last for approximately 12 months. Screening period is 2 weeks prior to randomization (Day -14 to Day 0), and each dose of either SARS-CoV-2 vaccine (BNT162b1) or placebo will be given intramuscularly (IM).
This is a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population. After randomization, the trial for each participant will last for approximately 13 months. Screening period is 2 weeks prior to randomization (Day -14 to Day 0), and two doses of either SARS-CoV-2 vaccine (BNT162b2) or placebo will be given intramuscularly (IM) separated by 21 days.
Description: SCR of SARS-CoV-2 serum neutralizing titers at 1-month after dose 2. Seroconversion is defined as ≥4-fold rise from before vaccination to 1-month post dose 2.
Measure: SARS-CoV-2 serum neutralizing titers - Seroconversion rates (SCR) Time: 1 Month after Dose 2Description: Compared with baseline before Vaccination 1, SCR of SARS-CoV-2 serum neutralizing titers at 1 week, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 serum neutralizing titers - SCR Time: 1 Week, 6 and 12 Months after Dose 2Description: GMT of SARS-CoV-2 serum neutralizing titers at 1 week, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 serum neutralizing titers - GMT Time: 1 Week, 6 and 12 Months after Dose 2Description: Compared with baseline before Vaccination 1, SCR of SARS-CoV-2 anti-S1 IgG antibody level at 1 week, 1, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 anti-S1 immunoglobulin G (IgG) antibody level - SCR Time: 1 Week, 1, 6 and 12 Months after Dose 2Description: GMT of SARS-CoV-2 anti-S1 IgG antibody level at 1 week, 1, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 anti-S1 IgG antibody level - GMT Time: 1 Week, 1, 6 and 12 Months after Dose 2Description: Compared with baseline before Vaccination 1, the GMFR of SARS-CoV-2 serum neutralizing antibody titers at 1 week, 1, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 serum neutralizing antibody level - Geometric mean fold rise (GMFR) Time: 1 Week, 1, 6 and 12 Months after Dose 2Description: Compared with baseline before Vaccination 1, GMFR of SARS-CoV-2 anti-S1 IgG antibody level at 1 week, 1, 6 and 12 months after dose 2.
Measure: SARS-CoV-2 anti-S1 IgG antibody level - GMFR Time: 1 Week, 1, 6 and 12 Months after Dose 2Description: Pain at the injection site, redness, and swelling as self-reported on diary cards.
Measure: Percentage of participants reporting local reactions Time: Within 7 Days and 14 Days after each vaccinationDescription: Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain as self-reported on diary cards.
Measure: Percentage of participants reporting systemic events Time: Within 7 Days and 14 Days after each vaccinationDescription: Percentage of participants with abnormal hematology laboratory values 1 and 7 days after dose 1, before dose 2, and 7 days after dose 2.
Measure: Hematology laboratory assessments Time: Day 1 and 7 Days after Dose 1, before Dose 2, and 7 Days after Dose 2Description: Percentage of participants with abnormal chemistry laboratory values 1 and 7 days after dose 1, before dose 2, and 7 days after dose 2.
Measure: Chemistry laboratory assessments Time: Day 1 and 7 Days after Dose 1, before Dose 2, and 7 Days after Dose 2Description: Percentage of participants with grading shifts in hematology laboratory assessments between baseline and 1 and 7 days after dose 1; and before dose 2 and 7 days after dose 2.
Measure: Hematology laboratory assessments Time: Day 1 and 7 Days after Dose 1; and before Dose 2 and 7 Days after Dose 2Description: Percentage of participants with grading shifts in chemistry laboratory assessments between baseline and 1 and 7 days after dose 1; and before dose 2 and 7 days after dose 2.
Measure: Chemistry laboratory assessments Time: Day 1 and 7 Days after Dose 1; and before Dose 2 and 7 Days after Dose 2Description: AEs from dose 1 to 1 month after the last dose.
Measure: Adverse events (AEs) Time: From Dose 1 through 1 Month after the last DoseDescription: SAEs from dose 1 to 6 months after the last dose.
Measure: Serious AEs (SAEs) Time: From Dose 1 through 6 Months after the last DoseThe trial has two parts: Part A is for dose ranging with dose escalation and de-escalation plus the evaluation of interim dose levels. It also includes dose ranging in older subjects. Part B is dedicated to recruit expansion cohorts with dose levels which are selected from data generated in Part A. The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 will be administered using a Prime/Boost (P/B) regimen. The vaccine BNT162c2 will also be administered using a Single dose (SD) regimen.
Description: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 21±2 days after the prime immunization.
Measure: The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): Time: 21 days following dose administrationDescription: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 28±4 days after the boost immunization. For BNT162c2 (SD): The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28±4 days after the immunization.
Measure: The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): Time: 28 days following dose administrationDescription: Functional antibody responses at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.
Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): Time: up to 162 days following dose administrationDescription: Fold increase in functional antibody titers 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.
Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): Time: up to 162 days following dose administrationDescription: Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 28±4 days, 63±5 days, and 162±7 days after the boost immunization.
Measure: For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): Time: up to 162 days following dose administrationDescription: Functional antibody responses at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
Measure: For BNT162c2 (SD): Time: up to 183 days following dose administrationDescription: Fold increase in functional antibody titers at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
Measure: For BNT162c2 (SD): Time: up to 183 days following dose administrationDescription: Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days, 21±2 days, 29±3 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
Measure: For BNT162c2 (SD): Time: up to 183 days following dose administrationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports